Latest Synthetic Biologics Inc. Stories
ROCKVILLE, Md., June 19, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 6(th) Annual OneMedForum New York Conference on Thursday, June 27, 2013 at The Metropolitan Club in New York City. Mr. Riley is scheduled to present at 8:40 a.m. (Eastern Time). A live webcast of Synthetic Biologics' presentation can be...
-- Keynote Speaker, Rhonda R. Voskuhl, M.D., Director of the Multiple Sclerosis Program at UCLA, to Address the Role of Estriol in the Treatment of Multiple Sclerosis -- ROCKVILLE, Md., June 13, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it will host a Multiple Sclerosis-Estriol Investor Day on Tuesday, June 25, 2013 from 9:00 a.m. to 11:00 a.m....
ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 2(nd) Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel. Mr. Riley is scheduled to present at 10:00 a.m. (Eastern Time). A live webcast of Synthetic Biologics' presentation can be...
ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights. Operational Highlights Emphasis on C. difficile (C. diff) Infection Prevention (SYN-004) In the U.S. each year, 24 million patients are administered IV antibiotics([1]) which may be...
ROCKVILLE, Md., April 19, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, reiterated that the Exclusive Channel Collaboration Agreement dated August 6, 2012 between the Company and Intrexon Corporation (Intrexon) remains in effect, as stated earlier today. This Exclusive Channel Collaboration Agreement governs a "channel collaboration" arrangement for the use of Intrexon's...
-- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md., April 16, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the year ended December 31, 2012 and summarized recent operational highlights. Operational Highlights: Expanding Infectious Disease Portfolio C....
-- Patent Expands Company's Patent Portfolio to Include Combination with Number One Selling Multiple Sclerosis Drug -- ROCKVILLE, Md., April 4, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,372,826 entitled, Estriol Therapy for Multiple Sclerosis and Other Autoimmune...
ROCKVILLE, Md., March 12, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley, will present at the 25(th) Annual ROTH Conference being held on March 17-20, 2013 at the Ritz-Carlton, Laguna Niguel in Dana Point, California. Mr. Riley is scheduled to present on Tuesday, March 19, 2013 at 1:30 p.m. (Pacific Time). A...
-- UCLA Professor to Bring Expertise to Company's Expanding Infectious Disease Program -- ROCKVILLE, Md., Feb. 26, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that Brad Spellberg, M.D., joined the Company's Scientific Advisory Board. Dr. Spellberg is an infectious disease specialist whose NIH-funded laboratory studies highly drug-resistant infections in...
ROCKVILLE, Md., Feb. 22, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its flupirtine sublicensee, Meda AB (Meda), has received a green light from the Food and Drug Administration (FDA) to conduct a Phase II proof of concept study for the treatment of fibromyalgia as reported in Meda's 2012 year-end report. Meda has announced that the randomized,...
